Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
25
×
clinical trials
25
×
deals
25
×
life sciences
national blog main
boston blog main
boston top stories
fda
san francisco blog main
national top stories
investing
san francisco top stories
new york blog main
startups
boston
new york top stories
cancer
indiana blog main
national
san diego blog main
boulder/denver blog main
boulder/denver top stories
indiana top stories
raleigh-durham blog main
roche
san diego top stories
seattle blog main
wisconsin blog main
wisconsin top stories
detroit blog main
detroit top stories
eli lilly
raleigh-durham top stories
seattle top stories
texas blog main
texas top stories
cancer immunotherapy
bristol-myers squibb
drugs
medical device
What
medicines
drug
roundup
bio
ipo
therapeutics
biotech
companies
disease
fda
new
cancer
company
days
deal
research
cash
developing
gene
million
pharma
potential
raised
treat
ago
ahead
alliance
approval
approved
asco
bacteria
candidate
crispr
diabetes
dicerna
digital
drugs
focus
growing
hasn’t
Language
unset
Current search:
biotech
×
deals
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
3 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com
4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More